A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy

Journal for Immunotherapy of Cancer
Tongjuan LiJianfeng Zhou

Abstract

The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved outcomes in MCL patients who were predicted not to respond to conventional therapy, but it is unlikely to be curative. Chimeric antigen receptor-modified T (CAR T) cells exhibit very effective function in elimination of relapsed/refractory B-cell lymphoid malignancies, we investigated their use in a patient with relapsed MCL. Here, we report a case of a refractory MCL in a patient who had relapsed after conventional chemotherapy and autologous CAR T cell therapy. The patient received multiple molecularly targeted therapies, including targeting BTK and BCL2, and haplo-identical CAR T (haplo-CAR T) cells from her daughter without previous allo-hematopoietic stem cell transplantation. Haplo-CAR T cells could effectively proliferate in vivo and had a clinically significant antitumor activity without serious side effects. The patient achieved a partial remission, with minimal residual disease. This case suggests that haplo-CAR T cell therapy can be effective in controlling lymphoma that failed to respond to autologous CAR T cell therapy and overcome limitation of autologo...Continue Reading

References

Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
Apr 2, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fabiola Cervantes-GomezVarsha Gandhi
Aug 1, 2015·Human Gene Therapy·Gunilla EnbladAngelica S I Loskog
Sep 22, 2015·Current Opinion in Hematology·Yinmeng YangTerry J Fry
Jan 29, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marco RuellaMariusz A Wasik
Jan 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew S DavidsJohn F Gerecitano
Jan 28, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Frederick L LockeWilliam Y Go
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James N KochenderferSteven A Rosenberg
Mar 29, 2018·The New England Journal of Medicine·Constantine S TamAndrew W Roberts

❮ Previous
Next ❯

Citations

May 3, 2019·AJNR. American Journal of Neuroradiology·H A ValandR K Tu
May 11, 2019·Clinical & Translational Immunology·Sherly MardianaPhillip Kevin Darcy
Jun 21, 2019·Current Hematologic Malignancy Reports·James N Gerson, Stefan K Barta
Dec 12, 2019·Frontiers in Oncology·Jiali ChengJianfeng Zhou
Jan 19, 2021·Cancer Immunology, Immunotherapy : CII·Xiaoxi ZhouJianfeng Zhou
Nov 5, 2021·Expert Review of Anticancer Therapy·Lidia GattoAlba Ariela Brandes

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
flow cytometry
xenograft

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.